查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542884

全球截癱市場 BCI（腦機介面） - 2024-2031

Global BCI (Brain-Computer Interfaces) in Paraplegia Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

截癱市場的全球BCI（腦機介面）市場在2023年達到2.385億美元，預計到2031年將達到3.462億美元，在2024-2031年預測期間複合年成長率為4.2%。

腦機介面是實現大腦與外部輸出之間直接通訊的系統。這些 BCI 設備由感測器組成，這些感測器測量神經元的電生理學並將訊息轉發到外部設備，例如電腦、機器人肢體或嵌入處理大腦訊號的軟體的任何其他外部系統。簡而言之，腦機介面允許使用者透過思維來控制設備。目前，許多神經技術公司正在積極測試這些設備，以將其投入臨床使用。對於截癱患者來說，腦機介面將提供移動、執行常規任務並提高其整體生活品質的機會。

市場動態：

司機

投資和研發活動不斷增加

用於截癱患者的 BCI（腦機介面）設備仍在開發中。多家神經科技公司正在努力將 BCI 設備投入臨床使用，其中一些公司已獲得監管機構的批准，可以在人體上進行測試。隨著力度不斷加大，預計該市場將以最高增速成長。

例如，2021年4月，IpsiHand成為第一個獲得美國食品藥物管理局（FDA）核准用於臨床的腦機介面產品。由 Neuroloutions, Inc. 開發的 IpsiHand 適用於上肢慢性中風患者的復健。該設備可在家庭和診所環境中使用。

繼 4 月 IpsiHand 獲得批准後，美國 FDA 已指定 Blackrock Neurotech 的 MoveAgain 腦機介面系統為突破性設備，用於行動障礙患者。借助此 BCI 系統，患者將能夠控制電腦、手機和輪椅。

一些這樣的公司正在積極對其 BCI 發明進行調查研究。例如，馬斯克 (Elon Musk) 經營的 Neuralink 公司在今年年初將其專有的 BCI 設備植入了第一位患者體內。 PRIME 研究旨在評估癱瘓患者用意念控制外部設備的設備的安全性和功能性。

這些突破性的創新預計將在不久的將來徹底改變截癱患者的治療方法。

例如，

限制

截癱患者的 BCI（腦機介面）市場受到多種因素的限制，例如缺乏足夠的批准用於臨床的產品、批准產品的高成本、高開發成本以及患者群體中的技術模糊性。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 投資和研發活動不斷增加
      • 截癱治療技術的採用不斷增加
    • 限制
      • 缺乏臨床核准的設備
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求
  • PESTEL分析
  • 專利分析
  • SWOT分析

第 6 章：按類型

  • 侵入性
  • 微創
  • 非侵入性

第 7 章：按技術

  • 微電極陣列 (MEA)
  • 皮質電圖（EcoG）
  • 腦電圖儀（EEG）
  • 功能近紅外光光譜 (fNIRS)
  • 其他

第 8 章：按申請

  • 行動協助
  • 溝通
  • 復健治療
  • 其他

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Neurolutions, Inc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Synchron
  • Neuralink
  • Blackrock Neurotech.
  • BrainGate.
  • Paradromics.
  • Cognixion
  • EMOTIV
  • Precision Neuroscience
  • Bitbrain Technologies

第 12 章：附錄

簡介目錄
Product Code: MD8600

Overview

The global BCI (brain-computer interfaces) in paraplegia market reached US$ 238.5 million in 2023 and is expected to reach US$ 346.2 million by 2031, growing at a CAGR of 4.2% during the forecast period 2024-2031.

Brain-computer interfaces are the systems that enable direct communication between the brain and the external output. These BCI devices consist of sensors that measure the electrophysiology of neurons and relay the information to an external device such as a computer, robotic limb, or any other external system embedded with software that processes the brain signals. In short, brain-computer interfaces allow the users to control devices by thinking. At present, many of the neurotechnology firms are actively testing these devices to bring them to clinical use. For paraplegic patients, brain-computer interfaces will provide an opportunity to move, perform regular tasks, and improve their overall quality of life.

Market Dynamics: Drivers

Rising investments and R&D activities

BCI (brain-computer interface) devices for paraplegia patients are still under development. Several neurotech companies are striving to bring BCI devices to clinical use, and some of these companies have received approval from the regulatory bodies to test on human subjects. As the efforts continue to rise, the market is anticipated to grow with the highest growth rate.

For instance, in April 2021, IpsiHand became the first brain-computer interface product to be approved for clinical use by the U.S. Food and Drug Administration (FDA). IpsiHand developed by Neuroloutions, Inc. is indicated for rehabilitation of upper extremity chronic stroke patients. The device can be used in home and clinic settings.

Followed by IpsiHand approval in April, the USFDA has designated Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives as a Breakthrough Device for use in patients with moving disability. With this BCI system, the patient will be able to control a computer, mobile, and wheelchair.

Several such companies are actively conducting investigational studies for their BCI inventions. For instance, Neuralink the Elon Musk-run company implanted their propreitory BCI device in their first patient early this year. The PRIME study aimed to evaluate the safety and functionality of the device in patients with paralysis to control external devices with their thoughts.

These groundbreaking innovations are anticipated to revolutionize the therapy for paraplegia patients in the near future.

For instance,

Restraints

The market for BCI (brain-computer interfaces) in paraplegia is restrained by several factors such as the lack of sufficient approved products for clinical use, the high cost of approved products, high development costs, and technology ambiguity in the patient population.

Segment Analysis

The global BCI (brain-computer interfaces) in paraplegia market is segmented based on type, technology, application, and region.

Electroencephalograph (EEG) in the technology segment accounted for approximately 43.7% of the global BCI (brain-computer interfaces) in paraplegia market share

The current technology that is being widely adopted for brain-computer interface development is electroencephalography (EEG). This has become an integral technology for the BCI systems due to its non-invasive nature which collects the neural signals. Moreover, it offers a cost-effective solution for the developer and to the patient, without any devoid of accuracy.

At present, the major companies that are actively developing BCI systems are focusing on EEG technology. For instance, the FDA-approved BCI device IpsiHand, uses an EEG headset to record the brain signals and control the movement produced in devices attached to extremities. Moreover, the BCI system developed by Cognixion uses EEG as a major recording technology in their devices. The devices by EMOTIV, another leading developer in this neurotech industry are employing EEG technology. Hence, the market for this technology is anticipated to have a significant growth rate in the forecast period.

Geographical Analysis

North America is expected to dominate the market with a share of 49.5% in the global BCI (brain-computer interfaces) in paraplegia market.

The North American region is expected to dominate the market due to its well-advanced healthcare infrastructure, and higher investments by market players supported by regulatory bodies for innovations. Moreover, the approved BCI systems in the current market are only available in the region, especially in the United States. For instance, IpsiHand is currently available for U.S. citizens with moving disabilities on a prescription basis.

The Neuralink BCI system is currently being clinically evaluated in the U.S., which means, the the device if found successful, will be made available first to U.S. paraplegia patients.

In addition, as the prevalence of paralysis is higher in the U.S., the opportunity for market players to develop their innovation is also high in the region. For instance, according to a study conducted by the Christopher & Dana Reeve Foundation in 2022, approximately 17 people are suffering from some kind of stroke per 1000 population in the U.S. which makes a total prevalence of 5.78 million patients in 2023.

Hence considering all these factors, North America is expected to dominate the market and experience significant growth in the forecast period. The region also projects itself as a major hub for investments in this novel neurotech market.

Market Segmentation

By Type

  • Invasive
  • Minimally Invasive
  • Non-Invasive

By Technology

  • Microelectrode Array (MEA)
  • Electrocorticography (EcoG)
  • Electroencephalograph (EEG)
  • Functional Near Infrared Spectroscopy (fNIRS)
  • Others

By Application

  • Mobility Assistance
  • Communication
  • Rehabilitation
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major players in the BCI (brain-computer interfaces) in paraplegia market include Neurolutions, Inc., Synchron, Neuralink, Blackrock Neurotech., BrainGate., Paradromics., Cognixion, EMOTIV, Precision Neuroscience, and Bitbrain Technologies among others.

Why Purchase the Report?

  • To visualize the global BCI (brain-computer interfaces) in paraplegia market segmentation based on type, technology, application, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of BCI (brain-computer interfaces) in paraplegia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global BCI (brain-computer interfaces) in paraplegia market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising investments and R&D activities
      • 4.1.1.2. Rising technology adoption for the treatment of paraplegia
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of clinically approved devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Invasive*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Minimally Invasive
  • 6.4. Non-Invasive

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Microelectrode Array (MEA)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Electrocorticography (EcoG)
  • 7.4. Electroencephalograph (EEG)
  • 7.5. Functional Near Infrared Spectroscopy (fNIRS)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Mobility Assistance*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Communication
  • 8.4. Rehabilitation
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.2. Germany
      • 9.3.5.3. UK
      • 9.3.5.4. France
      • 9.3.5.5. Italy
      • 9.3.5.6. Spain
      • 9.3.5.7. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.2. Brazil
      • 9.4.5.3. Argentina
      • 9.4.5.4. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.5.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.2. China
      • 9.5.5.3. India
      • 9.5.5.4. Japan
      • 9.5.5.5. South Korea
      • 9.5.5.6. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Neurolutions, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Synchron
  • 11.3. Neuralink
  • 11.4. Blackrock Neurotech.
  • 11.5. BrainGate.
  • 11.6. Paradromics.
  • 11.7. Cognixion
  • 11.8. EMOTIV
  • 11.9. Precision Neuroscience
  • 11.10. Bitbrain Technologies

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us